Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.
Video content above is prompted by the following questions:
Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use
May 14th 2025New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.
Read More